Research articles
Xiaowei Liu*, Fengli Zuo*, Jinen Song*, Leyi Tang, Xueyan Wang, Xinyu Liu, Hao Zhang, Zhankun Yang, Jing Jing, Xuelei Ma#, and Hubing Shi#. (2024) Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. Cell Discovery 10(1):16
Xiaowei Liu*, Jinen Song*, Hao Zhang*, Xinyu Liu*, Fengli Zuo, Yunuo Zhao, Yujie Zhao, Xiaomeng Yin, Xinyu Guo, Xi Wu, Hu Zhang, Jie Xu, Jianping Hu, Jing Jing, Xuelei Ma#, and Hubing Shi#. (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK-cell surveillance. Cancer Cell 41(2)
Dan Zheng*, Yanchu Li*, Linlin Song*, Tianyue Xu, Xian Jiang, Xiaomeng Yin, Yinbo He, Jinshun Xu, Xuelei Ma, Li Chai, Jie Xu, Jianping Hu, Peng Mi, Jing Jing#, Hubing Shi#. (2022) Improvement of radiotherapy with an ozone-carried liposome nano- system for synergizing cancer immune checkpoint blockade. Nano Today 47:101675.
Linlin Song*, Dan Zheng*, Jinshun Xu*, Tianyue Xu, Zhihui Liu, Huan Zhang, Yi Li, Yulan Peng#, and Hubing Shi# (2022) Improvement of TNBC immune checkpoint blockade with a microwave-controlled ozone release nanosystem. J Control. Release S0168-3659(22)00648-4. doi: 10.1016/j.jconrel.2022.09.053.
Xueyan Wang*, Jing Yu*, Xiaowei Liu*, Dan Luo, Yanchu Li, Linlin Song, Xian Jiang, Xiaomeng Yin, Yan Wang, Li Chai, Ting Luo, Jing Jing#, and Hubing Shi#(2022) PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer. Cell Rep. Med. 3(9):100741.
Manli Wang, Xuelan Chen, Ping Tan, Yiyun Wang, Xiangyu Pan, Tianhai Lin, Yong Jiang, Bo Wang, Huan Xu, Yuying Wang, Yucen Yang, Jian Wang, Lei Zhao, Jiapeng Zhang, Ailing Zhong, Yiman Peng, Jiajia Du, Qi Zhang, Jianan Zheng, Jingyao Chen, Siqi Dai, Feifei Na, Zhenghao Lu, Jiaming Liu, Xiaonan Zheng, Lu Yang, Peng Zhang, Ping Han, Qiyong Gong, Qian Zhong, Kai Xiao, Hanshuo Yang, Hongxin Deng, Yinglan Zhao, Hubing Shi, Jianghong Man, Maling Gou, Chengjian Zhao, Lunzhi Dai, Zhihong Xue, Lu Chen, Yuan Wang, Musheng Zeng, Canhua Huang, Qiang Wei0, Yuquan Wei, Yu Liu, and Chong Chen (2022) Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell 40(9):1044-1059.
Du Guo*, Huaichuan Duan*, Yan Cheng, Yueteng Wang, Jianping Hu#, and Hubing Shi# (2022) Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. Mol. Biomed. 3(1):12.
Xiaobo Zheng*, Jinen Song*, Chune Yu*, Zongguang Zhou*, Xiaowei Liu, Jing Yu, Guangchao Xu, Jiqiao Yang, Xiujing He, Xin Bai, Ya Luo, Yu Bao, Huifang Li, Lie Yang, Mingqing Xu, Nan Song, Xiaodong Su, Jie Xu, Xuelei Ma#, and Hubing Shi# (2022) Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis. Signal Transduct. Target Ther. 7(1):60.
Guangchao Xu*, Ya Luo*, Wenshuang Wu*, Xiaowei Liu*, Xin Yu, Yu Bao, Xiujing He, Jing Yu, Yanna Li, Jiqiao Yang, Rongjie Zhang, Chune Yu, Hongying Chen, Jie Xu, Jianping Hu, Jing Jing, and Hubing Shi (2022) The evolution of acquired resistance to BRAF inhibitor is sustained by IGF1-driven tumor vascular remodeling. J Invest. Dermatol. 142(2):445-458.
Zheng Dan, He Xiujing, Luo Ting, Zhong Xiaorong, Zheng Hong, Yang Jiqiao, Li Yanchu# and Jing Jing# (2021)Long Non-coding RNA BTG3-7:1 and JUND Co-regulate C21ORF91 to Promote Triple-Negative Breast Cancer Progress. Frontiers in Molecular Biosciences, 2021, 7: 380
Xin Bai, Xueyan Wang, Guozhen Ma, Jinen Song, Xiaowei Liu1, Xi Wu, Yujie Zhao, Xu Liu, Zhihui Liu1, Wei Zhang, Xin Zhao, Zirui Zheng, Jing Jing1# and Hubing Shi1# (2021) Improvement of PD-1 blockade efficacy and elimination of immune-related gastrointestinal adverse effect by mTOR inhibitor. Frontiers in Immunology: 5494
He, Xiujing, Jing Yu, and Hubing Shi#.(2021) Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Frontiers in pharmacology 12 (2021): 797852.
Chune Yu, Dan Luo, Jing Yu, Min Zhang, Xiaobo Zheng, Guangchao Xu, Jiaxin Wang, Huiling Wang, Yufei Xu, Ke Jiang, Jie Xu, Xuelei Ma, Jing Jing#, Hubing Shi# (2021) Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene (2021): 1-13.
Guangchao Xu, Ya Luo, Wenshuang Wu, Xiaowei Liu, Xin Yu, Yu Bao, Xiujing He, Jing Yu, Yanna Li, Jiqiao Yang, Rongjie Zhang, Chune Yu, Hongying Chen, Jie Xu, Jianping Hu, Jing Jing, Hubing Shi# (2021) The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling. Journal of Investigative Dermatology (2021).
Xiaowei Liu, Yanlin Feng, Jie Xu, Ying Shi, Jiqiao Yang, Rongjie Zhang, Jinen Song, Xin Bai, Xi Wu, Yu Bao, Ya Luo, Huifang Li, Li Chai, Changyang Gong, Yan Wang, Bo Chen, Jianping Hu, Yan Fu, Yongzhang Luo, Haiyuan Zhang#, Hubing Shi# (2021) Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. Journal of Controlled Release 332 (2021): 194-209.
Qing Luo, Huaichuan Duan, Hailian Yan, Xinyu Liu, Lianxin Peng, Yichen Hu, Wei Liu, Li Liang, Hubing Shi#, Gang Zhao#, Jianping Hu# (2021) Specifically Targeting Mtb Cell-Wall and TMM Transporter: The Development of MmpL3 Inhibitors. Current Protein and Peptide Science 22.4 (2021): 290-303.
Han Yao, Chushu Li, Fang He, Teng Song, Jean-Philippe Brosseau, Huanbin Wang, Haojie Lu, Caiyun Fang, Hubing Shi, Jiang Lan, Jing-Yuan Fang, Jie Xu (2021) A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. RSC Chemical Biology 2.1 (2021): 192-205.
Chune Yu, Min Zhang, Jinen Song, Xiaobo Zheng, Guangchao Xu, Yu Bao, Jiang Lan, Dan Luo, Jianping Hu#, Jingyi Jessica Li#, Hubing Shi# (2020) Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy. Molecular Biomedicine 1.1 (2020): 1-16.
Huai-Chuan Duan, Lian-Xin Peng, Yi-Chen Hu, Qing Luo, Xin-Yu Liu, Xin Sun, Li Liang, Ya Gan, Wei Liu, Hua Wan, Hu-Bing Shi#, Gang Zhao#, Jian-Ping Hu# (2020) The Advances of the Structure and Function of Indoleamine 2, 3-dioxygenase 1 and Its Inhibitors. Current Protein and Peptide Science 21.10 (2020): 1027-1039.
Zhixiang Wu, Lianxin Peng, Yichen Hu, Tao Xie, Hailian Yan, Hua Wan, Wei Liu, Li Liang, Zhenjian Xie, Kunping Liu, Hubing Shi#, Gang Zhao#, Jianping Hu# (2020) BP [dG]-induced distortions to DNA polymerase and DNA duplex: a detailed mechanism of BP adducts blocking replication. Food and Chemical Toxicology 140 (2020): 111325.
Xinyu Liu, Yiwen Zhang, Huaichuan Duan, Qing Luo, Wei Liu, Li Liang, Hua Wan, Shan Chang, Jianping Hu#, Hubing Shi# (2020) Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations. Frontiers in molecular biosciences 6 (2020): 164.
Xiao Yan,‡ Yafei Luo,‡ Wei Liu, Li Liang, Ya Gan, Zhongzhu Chen, Zhigang Xu, Hua Wan, Dianyong Tang#, Hubing Shi# and Jianping Hu# (2020) Strategy used to synthesize high activity and low Pd catalyst for Suzuki coupling reaction: an experimental and theoretical investigation. Physical Chemistry Chemical Physics 22.11 (2020): 6222-6230.
Ke Jiang, Genpeng Li, Wenjie Chen, Linlin Song, Tao Wei, Zhihui Li, Rixiang Gong, Jianyong Lei#, Hubing Shi#, and Jingqiang Zhu# (2020)Plasma exosomal miR-146b-5p and miR-222-3p are potential biomarkers for lymph node metastasis in papillary thyroid carcinomas. OncoTargets and therapy 13 (2020): 1311.
Wei Vivian Li, Shan Li, Xin Tong, Ling Deng, Hubing Shi#, and Jingyi Jessica Li# (2019) AIDE: annotation-assisted isoform discovery with high precision. Genome Res. 29(12):2056-2072.
Tao Xie*, Zhixiang Wu*, Jinke Gu, Runyu Guo, Xiao Yan, Huaichuan Duan, Xinyu Liu, Wei Liu, Li Liang, Hua Wan, Yafei Luo, Dianyong Tang, Hubing Shi# and Jianping Hu# (2019) The global motion affecting electron transfer in Plasmodium falciparum type II NADH dehydrogenases: a novel non-competitive mechanism for quinoline ketone derivative inhibitors. Phys Chem Chem Phys. 21(33):18105-18118.
Wei Liu, Jie Li, Ping Zhang, Qiaoyun Hou, Shi Feng, Lisheng Liu, Dawei Cui, Hubing Shi, Yan Fu, and Yongzhang Luo (2019) A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. Cancer Sci. 110(9):2941-2959.
Xin Sun, Li Liang, Jinke Gu, Wei Zhuo, Xiao Yan, Tao Xie, Zhixiang Wu, Xinyu Liu, Xiaojun Gou, Wei Liu, Gang He, Ya Gan, Shan Chang, Hubing Shi# & Jianping Hu# (2019) Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition and binding free energy. J Biomol Struct Dyn. 37(18):4801-4812.
Xiaowei Liu, Yanlin Feng, Guangchao Xu, Yang Chen, Ya Luo, Jinen Song, Yu Bao, Jiqiao Yang, Chune Yu, Yanna Li, Haoyu Ye, Bowen Ke, Bo Chen, Jianping Hu, Jie Xu, Huan Meng, Haiyuan Zhang#, and Hubing Shi# (2019) MAPK-Targeted Drug Delivered by a pH Sensitive MSNP Nanocarrier Synergizes with PD-1 Blockade in Melanoma without T-cell Suppression. Adv. Funct. Mater. 12(29):
Han Yao*, Jiang Lan*, Chushu Li*, Hubing Shi*, Jean-Philippe Brosseau, Huanbin Wang, Haojie Lu, Caiyun Fang, Yao Zhang, Lunxi Liang, Yu Xue & Jie Xu * (2019) Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Biomed. Eng. 3(4):306-317.
Huanbin Wang, Han Yao, Chushu Li, Hubing Shi, Jiang Lan, Zhaoli Li, Yao Zhang, Lunxi Liang, Jing-Yuan Fang & Jie Xu (2019) HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 15(1):42-50.
Lunxi Liang, Huanbin Wang, Hubing Shi, Zhaoli Li, Han Yao, Zhigao Bu, Ningning Song, Chushu Li, Dabin Xiang, Yao Zhang, Jilin Wang, Ye Hu, Qi Xu, Yanlei Ma, Zhongyi Cheng, Yingchao Wang, Shuliang Zhao, Jin Qian, Yingxuan Chen, Jing-Yuan Fang, Jie Xu. (2018) A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell Chem Biol. 2018 Jun 21;25(6):761-774.
Huanbin Wang, Han Yao, Chushu Li, Lunxi Liang, Yao Zhang, Hubing Shi, Chongzhi Zhou, Yingxuan Chen, Jing-Yuan Fang & Jie Xu (2017) PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. 6(7):e1327494.
Bjoern Titz, Anastasia Lomova, Allison Le, Willy Hugo, Xiangju Kong, Johanna ten Hoeve, Michael Friedman, Hubing Shi, Gatien Moriceau, Chunying Song, Aayoung Hong, Mohammad Atefi, Richard Li, Evangelia Komisopoulou, Antoni Ribas, Roger S Lo, and Thomas G Graeber (2016) JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2:16028.
Willy Hugo*, Hubing Shi*, Lu Sun*, Marco Piva*, ChunYing Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B. Dahlman, Douglas B. Johnson, Jeffrey A. Sosman, Antoni Ribas, and Roger S. Lo (2015) Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell 162(6):1271-85.
Anna C Obenauf, Yilong Zou, Andrew L Ji, Sakari Vanharanta, Weiping Shu, Hubing Shi, Xiangju Kong, Marcus C Bosenberg, Thomas Wiesner, Neal Rosen, Roger S Lo, Joan Massagué (2015) Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520(7547):368-72.
Gatien Moriceau*, Willy Hugo*, Aayoung Hong*, Hubing Shi*, Xiangju Kong, C Yu Clarissa, Richard C Koya, Ahmed A Samatar, Negar Khanlou, Jonathan Braun, Kathleen Ruchalski, Heike Seifert, James Larkin, Kimberly B Dahlman, Douglas B Johnson, Alain Algazi, Jeffrey A Sosman, Antoni Ribas, and Roger S Lo (2015) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27(2):240-56.
Hubing Shi*, Willy Hugo*, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley,Richard F. Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, and Roger S. Lo (2014) Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discov. 4:80-93.
Hubing Shi*, Aayoung Hong*, Xiangju Kong, Richard C. Koya, Chunying Song, Gatien Moriceau, Willy Hugo, Clarissa C. Yu, Charles Ng, Thinle Chodon, Richard A. Scolyer, Richard F. Kefford, Antoni Ribas, Georgina V. Long, and Roger S. Lo (2014) A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discov. 4:69-79.
Agnieszka Gembarska, Flavie Luciani, Clare Fedele, Elisabeth A Russell, Michael Dewaele, Stéphanie Villar, Aleksandra Zwolinska, Sue Haupt, Job de Lange, Dana Yip, James Goydos, Jody J Haigh, Ygal Haupt, Lionel Larue, Aart Jochemsen, Hubing Shi, Gatien Moriceau, Roger S Lo, Ghanem Ghanem, Mark Shackleton, Federico Bernal & Jean-Christophe Marine (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine 18:1239–1247.
Hubing Shi*, Gatien Moriceau*, Xiangju Kong, Richard C. Koya, Ramin Nazarian, Gulietta M. Pupo, Antonella Bacchiocchi, Kimberly B. Dahlman, Bartosz Chmielowski, Jeffrey A. Sosman, Ruth Halaban, Richard F. Kefford, Georgina V. Long, Antoni Ribas & Roger S. Lo (2012) Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discov. 2(5):414-424.
Hubing Shi, Gatien Moriceau*, Xiangju Kong*, Mi-Kyung Lee*, Hane Lee, Richard C. Koya, Charles Ng, Thinle Chodon, Richard A. Scolyer, Kimberly B. Dahlman, Jeffrey A. Sosman, Richard F. Kefford, Georgina V. Long, Stanley F. Nelson, Antoni Ribas & Roger S. Lo (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3:724.
Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay, Maayan Salton, Kimberly B. Dahlman, Madhavi Tadi, Jennifer A. Wargo, Keith T. Flaherty, Mark C. Kelley, Tom Misteli, Paul B. Chapman, Jeffrey A. Sosman, Thomas G. Graeber, Antoni Ribas, Roger S. Lo, Neal Rosen & David B. Solit (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480(7377):387-90.
Hubing Shi, Xiangju Kong, Antoni Ribas, and Roger S. Lo (2011) Combinational treatments that overcome PDGFRb-driven resistance of melanoma cells to V600EB-Raf inhibition. Cancer Res. 71(15):5067-74.
Wei Guo, Suzanne Schubbert, James Y. Chen, Bahram Valamehr, Sherly Mosessian, Hubing Shi, Nhi H. Dang, Consuelo Garcia, Mariana F. Theodoro, Marileila Varella-Garcia, and Hong Wu (2011) Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci U S A. 108(4):1409-14.
Ramin Nazarian*, Hubing Shi*, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant McArthur, Jeffrey A. Sosman, Antoni Ribas & Roger S. Lo (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468(7326):973-7.
Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Hubing Shi, Dan Feng, Yi Sun, Yun Liang, Yan Fu, Daifu Zhou, & Yongzhang Luo (2010) The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis. J Biol Chem. 285(51):40039-49.
Xiaofeng Wang, Xiaomin Song, Wei Zhuo, Yan Fu, Hubing Shi, Yun Liang, Maomeng Tong, Guodong Chang, & Yongzhang Luo (2009) The Regulatory Mechanism of Hsp90alpha Secretion and its Function in Tumor Malignancy. Proc Natl Acad Sci U S A. 106(50):21288-93.
Yan Fu, Yang Chen, Xu Luo, Yun Liang, Hubing Shi, Lei Gao, Shunli Zhan, Daifu Zhou, Yongzhang Luo (2009) The Heparin Binding Motif of Endostatin Mediates Its Interaction with Receptor Nucleolin. Biochemistry. 48(49):11655-63.
Yujie Huang, Nan Song, Yanping Ding, Shaopeng Yuan, Xuhui Li, Hongchen Cai, Hubing Shi, Yongzhang Luo (2009). Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 69(19):7529-37.
Nan Song, Yujie Huang, Hubing Shi, Shaopeng Yuan, Yanping Ding, Xiaomin Song, Yan Fu, Yongzhang Luo (2009). Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res. 69(15):6057-64.
Shaopeng Yuan, Yan Fu, Xiaofeng Wang, Hubing Shi, Yujie Huang, Xiaomin Song, Ling Li, Nan Song, & Yongzhang Luo (2008). “Voltage dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis” FASEB J. 22(8):2809-20.
Shi, Hubing, et al. “Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin.” Blood 110.8 (2007): 2899-2906.
Yujie Huang, Hubing Shi, Hao Zhou, Xiaomin Song, Shaopeng Yuan, & Yongzhang Luo (2006). “The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin” Blood 107(9): 3564-71.
* These authors contributed equally to these work.
Reviews and Chapters
Xiujing He, Xiaowei Liu, Fengli Zuo, Hubing Shi, Jing Jing (2023) Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Seminars in Cancer Biology 88 (2023):187-200.
Jie Xu, Jean-Philippe Brosseau, Hubing Shi (2020) Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene 39.48 (2020): 7106-7113.
Yiting Wang, Hubing Shi#, Huan Meng#, Jie Xu# (2020) Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies. Frontiers in Pharmacology 11 (2020): 1578.
Ya Luo, Jiqiao Yang, Jing Yu, Xiaowei Liu, Chune Yu, Jianping Hu, Hubing Shi#, Xuelei Ma# (202) Long non-coding RNAs: emerging roles in the immunosuppressive tumor microenvironment. Frontiers in oncology 10 (2020): 48.
Hubing Shi, Jiang Lan, Jiqiao Yang (2020) Mechanisms of Resistance to Checkpoint Blockade Therapy. Adv Exp Med Biol. 2020;1248:83-117.
Chune Yu, Xiaowei Liu, Jiqiao Yang, Min Zhang, Hongyu Jin, Xuelei Ma#, and Hubing Shi# (2019) Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Front Immunol. 2019; 10: 990.
Jiqiao Yang, Xiujing He, Qing Lv, Jing Jing#, and Hubing Shi# (2019) Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol. 10: 726.
Roger S. Lo and Hubing Shi (2014) Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma. Molecular Diagnostics for Melanoma, 1102:163-74.